Lyra Therapeutics, Inc.
LYRA
$0.1128
$0.00110.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 183.00K | 209.00K | 195.00K | 598.00K | 532.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 183.00K | 209.00K | 195.00K | 598.00K | 532.00K |
| Cost of Revenue | 4.88M | 6.36M | 5.90M | 13.26M | 18.24M |
| Gross Profit | -4.69M | -6.15M | -5.71M | -12.67M | -17.71M |
| SG&A Expenses | 3.26M | 3.61M | 3.93M | 5.14M | 5.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.14M | 9.98M | 9.83M | 18.40M | 24.06M |
| Operating Income | -7.96M | -9.77M | -9.64M | -17.81M | -23.52M |
| Income Before Tax | -8.54M | -10.97M | -11.87M | -48.12M | -22.44M |
| Income Tax Expenses | 4.00K | 6.00K | 7.00K | 12.00K | 14.00K |
| Earnings from Continuing Operations | -8.55M | -10.98M | -11.87M | -48.13M | -22.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.55M | -10.98M | -11.87M | -48.13M | -22.45M |
| EBIT | -7.96M | -9.77M | -9.64M | -17.81M | -23.52M |
| EBITDA | -7.83M | -9.62M | -9.60M | -17.66M | -23.39M |
| EPS Basic | -0.13 | -0.17 | -0.18 | -0.74 | -0.35 |
| Normalized Basic EPS | -0.07 | -0.09 | -0.09 | -0.16 | -0.22 |
| EPS Diluted | -0.13 | -0.17 | -0.18 | -0.74 | -0.35 |
| Normalized Diluted EPS | -0.07 | -0.09 | -0.09 | -0.16 | -0.22 |
| Average Basic Shares Outstanding | 65.76M | 65.51M | 65.46M | 65.46M | 64.01M |
| Average Diluted Shares Outstanding | 65.76M | 65.51M | 65.46M | 65.46M | 64.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |